Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360698 · ClinicalTrials.gov registry record · Phase 4
Insulin Glulisine in Type 2 Diabetic Patients
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 106
- Enrollment target
NCT00360698: Completed Phase 4 study, sponsored by Sanofi.
NCT00360698 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 106 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00360698, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 106 participants
- Enrollment target
Study Summary
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.
Primary Outcome
Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%
Interventions
- DRUG Metformin
- DRUG Insulin Glargine
- DRUG Glimepiride
- DRUG Insulin Glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
What the finished NCT00360698 record still lists
NCT00360698 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT00360698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00360698 about?
NCT00360698 is a clinical study titled "Insulin Glulisine in Type 2 Diabetic Patients". To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.
What is the current status of trial NCT00360698?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 106 participants. The study started on 2006-07. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00360698?
The interventions under investigation include: Metformin (DRUG), Insulin Glargine (DRUG), Glimepiride (DRUG), Insulin Glulisine (DRUG).
Who is sponsoring clinical trial NCT00360698?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00360698's enrollment target sits among peer trials
106 747th of 2000 higher than 1,252 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia